Advertisement

Hypophysen- und Hypothalamushormone

  • Ulrich Schwabe

Zusammenfassung

Hauptvertreter der Hypophysen- und Hypothalamushormone sind Gonadotropine, Wachstumshormon und Vasopressinanaloga. Der größte Teil der Verordnungskosten entfällt im Jahr 2003 auf die Gonadotropine, die einen erneuten kräftigen Verordnungszuwachs aufwiesen. Bei den bisher umsatzmäßig führenden Wachstumshormonpräparaten fiel der Anstieg etwas geringer aus.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Collins J (2003): A turbulent area. Fertil Steril 80:1117–1120.PubMedCrossRefGoogle Scholar
  2. Drake WM, Howell SJ, Monson JP, Shalet SM (2001): Optimizing gh therapy in adults and children. Endocr Rev 22:425–450.PubMedCrossRefGoogle Scholar
  3. Finkelstein BS, Imperiale TF, Speroff T, Marrero U, Radcliffe DJ, Cuttler L (2002): Effect of growth hormone therapy on height in children with idiopathic short stature: a meta-analysis. Arch Pediatr Adolesc Med 156:230–240.PubMedGoogle Scholar
  4. Frydman R, Howies CM, Truong F (2000): A double-blind, radomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. The French Multicentre Trialists. Hum Reprod 15: 520–525.Google Scholar
  5. International Recombinant Human Chorionic Gonadotropin Study Group (2001): Induction of ovulation in World Health Organization group II anovulatory women undergoing follicular stimulation with recombinant human follicle-stimulating hormone: a comparison of recombinant human chorionic gonadotropin (rhCG) and urinary hCG. Fertil Steril 75:1111–1118.CrossRefGoogle Scholar
  6. Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G, Hinds CJ (1999): Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 341: 785–792.PubMedCrossRefGoogle Scholar
  7. Van Wely M, Westergaard LG, Bossuyt PMM, van der Ween F (2003a): Effectiveness of human menopausal gonadotropin versus recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles: a meta-analysis. Fertil Steril 80:1086–1093.PubMedCrossRefGoogle Scholar
  8. Van Wely M, Byram N, van der Ween F (2003b): Recombinant FSH in alternative doses or versus urinary gonadotrophins for ouvlation induction in subfertility aossociated with polycystic ovary syndrome: a systematic review based on a Cochrane review. Hum Reprod 18:1143–1149.PubMedCrossRefGoogle Scholar
  9. Van Wely M, Westergaard LG, Bossuyt PMM, van der Veen F (2004): Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. The Cochrane Database Syst Rev 2004(1).Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • Ulrich Schwabe
    • 1
  1. 1.Pharmakologisches Institut der Universität HeidelbergHeidelberg

Personalised recommendations